<DOC>
	<DOC>NCT02311088</DOC>
	<brief_summary>Ticagrelor treatment is associated with increased rates of dyspnea, where previous studies have implied a possible role of adenosine. The purpose of this study is to determine if the caffeine-antagonist is effective in reducing dyspnea related to ticagrelor.</brief_summary>
	<brief_title>Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor</brief_title>
	<detailed_description />
	<mesh_term>Dyspnea</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<criteria>Age â‰¥ 18 years Recent acute coronary syndrome with ongoing ticagrelor treatment Stabilized clinical condition with no plans of additional revascularization Dyspnea with onset after start of ticagrelor treatment Willingness to abstain from caffeine intake (e.g. coffee, tea, colatype beverages; other foods, nutritional supplements or medications containing caffeine) for the duration of the study Provision of signed informed consent form Chronic obstructive pulmonary disease, asthma or other known pulmonary disease requiring daily medical therapy Obstructive sleep apnea syndrome requiring therapy Ongoing signs and symptoms of heart failure*, or evidence of moderately to severely reduced left ventricular (LV) function Renal failure, glomerular filtration rate (GFR) &lt;30 or on dialysis Pregnancy or lactation Known allergy to ticagrelor, or caffeine, or known intolerance of caffeine Ongoing treatment with any of the following: quinolone antibiotics, fluvoxamine, phenylpropanolamine, carbamazepine, clozapine, lithium, nonsteroidal antiinflammatory drugs (NSAIDs); or any drug containing theophylline or caffeine. Any condition that seriously increases the risk of noncompliance or loss of followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>